SynthesisCancer medicine2025
Association Between Sensorineural Hearing Loss and Neurocognitive Performance in Survivors of Childhood Cancer: A Systematic Review and Meta-Analysis.
Synthesis in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundVarious studies have shown that sensorineural hearing loss (SNHL) is associated with neurocognitive impairment among childhood cancer survivors, though prior studies are limited by small sample sizes and inconsistent methods.
objectiveThis systematic review and meta-analysis aimed to quantify neurocognitive differences between survivors with severe SNHL (s-SNHL) and those without.
methodsStudies were included if they evaluated childhood cancer survivors (diagnosed ≤ 21 years), were ≥ 2 years posttreatment, received cranial radiation and/or platinum-based chemotherapy, used validated neurocognitive tests, and included survivors with and without SNHL. Methods and reporting adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Databases searched included PubMed, Web of Science, Cochrane, Scopus, PsycINFO, and Embase. Study quality was assessed using an adapted version of the Newcastle-Ottawa Scale. We collected study details, including authors, year, neurocognitive tests used, sample sizes, and group scores (means and standard deviations [SD]). Pooled mean differences (MD) and 95% confidence intervals (95% CI) were calculated using standard scores (mean = 100, SD = 15) and random-effects models.
resultsOf 1012 records identified, nine studies were included in the analyses, with 503 childhood cancer survivors with s-SNHL and 1553 survivors without s-SNHL. Compared to survivors without s-SNHL, survivors with s-SNHL scored lower on measures of overall intellectual functioning (MD = -8.1, 95% CI = -10.0, -6.2), verbal reasoning (MD = -9.7, 95% CI = -11.4, -7.9), perceptual reasoning (MD = -6.6, 95% CI = -11.1, -2.1), working memory (MD = -5.3, 95% CI = -7.1, -3.4), processing speed (MD = -6.3, 95% CI = -9.9, -2.6), short-term visual memory (MD = -6.0, 95% CI = -8.2, -3.7), and reading (MD = -6.2, 95% CI = -7.9, -4.5).
conclusionsSevere SNHL is associated with significant neurocognitive deficits in childhood cancer survivors. Routine hearing screening and timely neurocognitive assessments are recommended to identify and address these impairments.
trial registrationPROSPERO: CRD42023440952.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.